Cargando…
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models
The COVID-19 pandemic caused by SARS-CoV-2 has made the development of safe and effective vaccines a critical priority. To date, four vaccines have been approved by European and American authorities for preventing COVID-19, but the development of additional vaccine platforms with improved supply and...
Ejemplares similares
-
Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms
por: D’Alessio, Federico, et al.
Publicado: (2023) -
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19
por: Aurisicchio, Luigi, et al.
Publicado: (2023) -
A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats
por: Conforti, Antonella, et al.
Publicado: (2023) -
Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma
por: Impellizeri, Joseph A., et al.
Publicado: (2018) -
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
por: Salvatori, Erika, et al.
Publicado: (2022)